Traders should anticipate near-term share price pressure due to dilution from the new issuance, especially given recent insider selling. Monitor for exercise of the underwriters' option, which would increase dilution. Use of proceeds may provide insight into pipeline development timelines.
APGE drugs
APGE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 25 $78.53entry
- T+1 · 8mo ago −0.14%α +1.63% · $78.42
- T+5 · 8mo ago +7.27%α +7.51% · $84.24
- T+20 · 7mo ago +12.43%α +4.57% · $88.29
- T+60 · 5mo ago +68.78%α +55.33% · $132.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Apogee Therapeutics priced an underwritten public offering of 5,000,000 shares at $70.00 per share, raising approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 750,000 shares. The offering is expected to close on March 26, 2026, subject to customary conditions.
Key Financial Metrics
Key Facts
- Apogee Therapeutics is offering 5,000,000 shares of common stock at $70.00 per share.
- Gross proceeds from the offering are expected to be approximately $350 million.
- Underwriters have a 30-day option to purchase up to an additional 750,000 shares.
- The offering is expected to close on March 26, 2026, subject to customary closing conditions.
- Jefferies, TD Cowen, Stifel, and Guggenheim Securities are joint book-running managers.
Financial Impact
$350 million in gross proceeds before expenses; potential for up to $402.5 million if underwriters exercise full option (750,000 additional shares at $70).
Risk Factors
- Significant equity dilution for existing shareholders.
- Potential downward pressure on stock price post-offering due to increased supply and recent insider selling.
- Forward-looking statements about clinical programs are speculative and subject to development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261899 |
Track record
31 reports on APGE
9 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers